Rakovina Therapeutics, a biopharmaceutical research company focused on developing innovative cancer treatments, has secured $1.5M in new funding. The capital will advance its work on therapies that target the DNA-damage response (DDR), a critical area in oncology.
The company distinguishes itself by integrating advanced Artificial Intelligence (AI) platforms into its research. This AI-powered approach allows Rakovina Therapeutics to review and optimize drug candidates at a significantly greater pace than traditional methods, aiming to accelerate the discovery and development of new oncology treatments.
.png&w=3840&q=75)
